{"id":"regular-management-levosimendan","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levosimendan binds to cardiac troponin C and enhances the sensitivity of contractile proteins to calcium, thereby improving myocardial contractility. It also has vasodilatory properties through opening of ATP-sensitive potassium channels. When combined with regular management protocols, it provides inotropic support in acute heart failure while reducing systemic and pulmonary vascular resistance.","oneSentence":"Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, used as adjunctive therapy in acute decompensated heart failure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:34.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure (adjunctive therapy)"},{"name":"Cardiogenic shock"}]},"trialDetails":[{"nctId":"NCT03189901","phase":"PHASE4","title":"Early Management Strategies of Acute Heart Failure for Patients With NSTEMI","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-07-01","conditions":"Early Management, Acute Heart Failure, NSTEMI - Non-ST Segment Elevation MI","enrollment":470}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Regular management+Levosimendan","genericName":"Regular management+Levosimendan","companyName":"Qilu Hospital of Shandong University","companyId":"qilu-hospital-of-shandong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, used as adjunctive therapy in acute decompensated heart failure. Used for Acute decompensated heart failure (adjunctive therapy), Cardiogenic shock.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}